Critical Analysis: Aclarion (ACON) and The Competition

Aclarion (NASDAQ:ACON) is one of 93 publicly-traded companies in the “Medical Services” industry, but how does it compare to its peers? We will compare Aclarion to related companies based on the strength of its earnings, risk, profitability, institutional ownership, dividends, valuation and analyst recommendations.

Profitability

This table compares Aclarion and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,908.50%	-67.53%	-63.01%
Aclarion Competitors	-958.98%	-59.14%	-12.35%

Volatility & Risk

Aclarion has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Aclarion’s peers have a beta of 1.53, indicating that their average share price is 53% more volatile than the S&P 500.

Insider & Institutional Ownership

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 58.1% of shares of all “Medical Services” companies are owned by institutional investors. 0.8% of Aclarion shares are owned by company insiders. Comparatively, 13.2% of shares of all “Medical Services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Aclarion and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aclarion	$67,483.00	-$6.99 million	-0.41
Aclarion Competitors	$9.95 billion	$239.88 million	15.54

Aclarion’s peers have higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Aclarion and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	1	0	0	1.50
Aclarion Competitors	644	2507	5139	185	2.57

Aclarion presently has a consensus target price of $11,758.50, suggesting a potential upside of 193,137.47%. As a group, “Medical Services” companies have a potential upside of 11.41%. Given Aclarion’s higher probable upside, research analysts plainly believe Aclarion is more favorable than its peers.

Summary

Aclarion peers beat Aclarion on 12 of the 13 factors compared.

Aclarion Company Profile

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.